Nordicus Partners NORD
OTC NORD
$3.50 -0.52 (-12.94%)
At close: Oct 23, 2026 · 4:00 PM EDT

Nordicus Partners (NORD) Return on Capital Employed [ROCE] (2011 - 2026)

Updated

Nordicus Partners' Return on Capital Employed [ROCE] came in at -6.00% for fiscal Q1 2027 (quarter ended Jun 30, 2026), down 1.12 percentage points from -4.88% a year earlier and down 0.13 percentage points from the prior quarter.

Analysis

Nordicus Partners (NORD) Return on Capital Employed [ROCE] (2011 - 2026) Analysis & Trends

For FY2026 (ended Mar 31, 2026), Nordicus Partners' Return on Capital Employed [ROCE] was -6.10%, up 2.25 percentage points from FY2025.

  • Return on Capital Employed [ROCE] has increased in each of the last three fiscal years, with a five-year change of +5.45 percentage points (FY2021 to FY2026).
  • Going back by fiscal year, Return on Capital Employed [ROCE] was -8.35% in FY2025 (+25.64 pp), -33.99% in FY2024 (+6742.03 pp), -6776.02% in FY2023 (-6545.43 pp) and -230.60% in FY2022 (-219.05 pp).
  • The fiscal Q1 2027 figure represents the lowest quarterly Return on Capital Employed [ROCE] since fiscal Q4 2024.
  • Year-over-year, Return on Capital Employed [ROCE] has declined for five consecutive quarters, with an average year-over-year change of +45.26 percentage points over the last eight quarters.
  • The fastest year-over-year change in Return on Capital Employed [ROCE] over five years came in fiscal Q4 2024 (a gain of 269570.63 percentage points), and the weakest in fiscal Q4 2023 (a drop of 269352.07 percentage points).
  • Business Quant data shows NORD's Return on Capital Employed [ROCE] at -5.87% (Q4 2026), -5.41% (Q3 2026) and -5.60% (Q2 2026) in the three fiscal quarters before Q1 2027.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 46.74%
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 17.52%
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 17.92%
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 6.28%
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 19.32%
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 16.76%
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 16.66%
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn -5.97%
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 11.86%
10 Nordicus Partners 68.05 Mn 67.52 Mn - -6.00%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -6.00%
Mar 31, 2026 -5.87%
Dec 31, 2025 -5.41%
Sep 30, 2025 -5.60%
Jun 30, 2025 -4.88%
Mar 31, 2025 -4.57%
Dec 31, 2024 -5.37%
Sep 30, 2024 -4.48%
Jun 30, 2024 -4.57%
Mar 31, 2024 -17.32%
Dec 31, 2023 -160.74%
Sep 30, 2023 -202.33%
Jun 30, 2023 -389.74%
Mar 31, 2023 -269,587.95%
Sep 30, 2022 -7,296.47%
Jun 30, 2022 -2,624.44%
Mar 31, 2022 -235.88%
Jun 30, 2021 -391.95%
Mar 31, 2021 -289.78%
Dec 31, 2020 -98.80%
API Access

Nordicus Partners Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=NORD&period=max&api_key=YOUR_API_KEY